North America Respiratory Inhalers Market

The North America respiratory inhalers market is expected to grow from US$ 12,747.47 million in 2022 to US$ 17,991.07 million by 2028. It is estimated to register a CAGR of 5.9% from 2022 to 2028. 

Growing Adoption of Generic Inhalers Fueling North America Respiratory Inhalers Market Growth

Inhaled medicines, which form a major line of treatment in asthma and COPD patients, are administered through inhalers. Patients suffering from asthma and COPD often need one or more inhalers daily to keep their airways healthy. Therefore, healthcare professionals are concerned about switching between medications as it can negatively impact disease control through low adherence and misuse of aerosol delivery device types. With increasing pressure on healthcare budgets and the simultaneous expiration of patents on established inhalation treatments, several generic replacement products are being manufactured and supplied across the region. Several inhalants that are used to treat asthma include generic formulations, such as albuterol, levalbuterol, ipratropium, budesonide, and fluticasone/salmeterol. The generic inhalers are bioequivalent to the branded versions and have the same effect on the body. The number of generic asthma inhalers continues to increase as patents expire. As more generic drugs are entering the market, increased competition is expected, which, in turn, leads to reduced costs of drugs. Cost reductions can also result from the launch of an “approved generic drug.” Thus, the growing adoption of generic inhalers and asthma medications is improving medication adherence, thereby driving the North America respiratory inhalers market.

North America Respiratory Inhalers Market Overview

The North America respiratory inhalers market is segmented into the US, Canada, and Mexico. The US held the largest share of the North America respiratory inhalers market in 2021. The continuously rising incidence of respiratory disorders is expected to fuel the growth of this market. Currently, asthma and chronic obstructive pulmonary disease (COPD) are major health burdens in the US. Asthma is a chronic inflammatory disorder due to airway narrowing and obstruction. COPD is due to obstruction of airflow from the lungs, which causes chronic inflammatory lung disease. Smoking is the main cause of COPD in the US. The increasing prevalence of smoking in the US is driving the respiratory inhalers market. According to the Centers for Disease Control and Prevention (CDC), in 2020, ~5.0% of adults were diagnosed with COPD, emphysema, or chronic bronchitis in the United States. Approximately 25 million people were affected with asthma, and 14.8 million had COPD. COPD was the fourth leading cause of death in the United States in 2018. Furthermore, ~1 in every 10 infants born in 2020 were preterm births. Thus, the growing prevalence of chronic respiratory disorders and preterm births in the United States is driving the North America respiratory inhalers market.

North America Respiratory Inhalers Market Revenue and Forecast to 2028 (US$ Million)

North America Respiratory Inhalers Strategic Insights

Strategic insights for the North America Respiratory Inhalers provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Respiratory Inhalers Report Scope

North America Respiratory Inhalers Regional Insights

The geographic scope of the North America Respiratory Inhalers refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

North America Respiratory Inhalers Market Segmentation

The North America respiratory inhalers market is segmented based on product type, technology, disease indication, and country.

Based on product type, the North America respiratory inhalers market is segmented into nebulizers, metered dose inhalers (MDI), and dry powder inhalers. The dry powder inhalers segment held the largest share of the North America respiratory inhalers market in 2022.

Based on technology, the North America respiratory inhalers market is bifurcated into manually operated inhalers and digitally operated inhalers. The manually operated inhalers segment held a larger share of the North America respiratory inhalers market in 2022.  

Based on disease indication, the North America respiratory inhalers market is segmented into asthma, COPD, pulmonary arterial hypertension, and others. The asthma segment held the largest share of the North America respiratory inhalers market in 2022.

Based on country, the North America respiratory inhalers market has been categorized into the US, Canada, and Mexico. The US dominated the North America respiratory inhalers market in 2022.  

AstraZeneca Plc; Beximco Pharmaceuticals Ltd.; Boehringer Ingelheim International GmbH; Cipla Ltd; GSK Plc; Koninklijke Philips NV; OMRON Corp; OPKO Health, Inc; PARI Respiratory Equipment, Inc.; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the North America respiratory inhalers market.